INNT
TOTAL INVALIDATION PROCESSED BY THE IB
25/12/2025
Voltar para busca
Dado oficial do USPTO
PEMPFIX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
26/12/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
02/06/2016
Data de registro
10/04/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/10/2024
Última transação
26/12/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
ES
Examinador
TOOLEY,DAVID E
Unidade examinadora
M30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
N. S. (pessoa física)
Immungenetics AG
Representantes
Holiday W. Banta Ice Miller LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and biochemical pharmaceutical preparations for the treatment of or prevention against inflammatory diseases, cancer, infectious diseases, fungal diseases, diseases caused by parasites, eye diseases, diseases of the central and peripheral nervous systems, cardiovascular diseases, diseases affecting the immune system, genetic diseases, single gene disorders, mouth, teeth, skin, hair and ear diseases, bone and blood diseases as well as reproductive system diseases; pharmaceutical and biochemical pharmaceutical preparations for contraception; biochemical and chemical pharamceuticals preparations for use with inflammatory diseases, in particular for use with chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against inflammatory diseases, in particular for prevention against chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory skin diseases; biochemical and chemical products for prevention against psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for prevention against blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus diseases; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceuticals preparations for prevention against subepidermal bullous autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoide, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory diseases of the central nervous systems, in particular for prevention against multiple sclerosis; biochemical and chemical pharmaceuticals preparations for the treatment of inflammatory diseases, in particular for the treatment of chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory skin diseases, in particular for the treatment of psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for the treatment of blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus diseases; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceutical preparations for the treatment of subepidermal bullae autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoid, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory diseases of the central nervous system, in particular for the treatment of multiple sclerosis; topical and transdermal pharmaceuticals, in particular creams, dispersions, lotions, ointments, fluids, solutions, sprays, plasters, lacquer and filmforming solutions, for the prevention and treatment of skin diseases of the uppermost skin layer or the upper skin layers; surface treatment pharmaceuticals preparations for use as treatments of immune system diseases, inflammatory diseases, skin, hair and ear diseases; oral administration pharmaceuticals preparations, in particular pills, tablets, lozenges, capsules, liquids, solutions, drops, for the prevention and treatment of central nervous system diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
04/12/2025
INPC
INVALIDATION PROCESSED
04/12/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
25/06/2025
C71T
CANCELLED SECTION 71
25/10/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/04/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
30/07/2021
CHLD
CHANGE OF OWNER RECEIVED FROM IB
30/04/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/07/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
24/08/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
30/07/2018
FIMP
FINAL DISPOSITION PROCESSED
30/07/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/07/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
10/04/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/02/2018
PUBO
PUBLISHED FOR OPPOSITION
23/01/2018
GPNX
NOTIFICATION PROCESSED BY IB
19/01/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/01/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/01/2018
NPUB
NOTICE OF PUBLICATION
03/01/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/12/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/11/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/11/2017
ALIE
ASSIGNED TO LIE
19/11/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/11/2017
RFNT
REFUSAL PROCESSED BY IB
18/08/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/08/2017
RFRR
REFUSAL PROCESSED BY MPU
01/08/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/08/2017
CNRT
NON-FINAL ACTION WRITTEN
31/07/2017
MAFR
APPLICATION FILING RECEIPT MAILED
25/07/2017
DOCK
ASSIGNED TO EXAMINER
19/07/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/07/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/07/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PEMPFIX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.